Nodality lands $10M to treat malignancies and autoimmune disease

Nodality, developer of diagnostics used to identify bloodstream malignancies and autoimmune disorders, has brought in $10 million of a $13.5 million round of equity. Based in South San Francisco, the company is backed by Kleiner Perkins Caufield & Byers, Maverick Capital and TPG Biotechnology.

blog comments powered by Disqus